Xabitor 80 Tablet contains Febuxostat 80 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and subsequently to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout flares and the formation of urate crystals in joints and tissues. Xabitor 80 is typically prescribed for patients who are intolerant to or inadequately managed with other urate-lowering therapies such as allopurinol. The recommended dosage should be individualized based on serum uric acid levels and renal function, with regular monitoring advised to assess therapeutic efficacy and safety. Common adverse effects may include liver function abnormalities, nausea, rash, and joint pain, necessitating periodic liver enzyme tests during treatment. Caution is advised in patients with a history of cardiovascular disease, as febuxostat has been associated with an increased risk of cardiovascular events in some studies. Xabitor 80 should be used under strict medical supervision, ensuring appropriate dose adjustments and monitoring to optimize treatment outcomes and minimize potential risks.